The Experts below are selected from a list of 288 Experts worldwide ranked by ideXlab platform
Damian J. Tyler - One of the best experts on this subject based on the ideXlab platform.
-
hyperpolarized magnetic resonance shows that the anti ischemic drug meldonium leads to Increased Flux through pyruvate dehydrogenase in vivo resulting in improved post ischemic function in the diabetic heart
NMR in Biomedicine, 2021Co-Authors: Dragana Savic, Vicky Ball, David Hauton, M. Kate Curtis, Lisa C. Heather, L Holster, Kerstin N. Timm, Damian J. TylerAbstract:The diabetic heart has a decreased ability to metabolize glucose. The anti-ischemic drug meldonium may provide a route to counteract this by reducing l-carnitine levels, resulting in improved cardiac glucose utilization. Therefore, the aim of this study was to use the novel technique of hyperpolarized magnetic resonance to investigate the in vivo effects of treatment with meldonium on cardiac metabolism and function in control and diabetic rats. Thirty-six male Wistar rats were injected either with vehicle, or with streptozotocin (55 mg/kg) to induce a model of type 1 diabetes. Daily treatment with either saline or meldonium (100 mg/kg/day) was undertaken for three weeks. in vivo cardiac function and metabolism were assessed with CINE MRI and hyperpolarized magnetic resonance respectively. Isolated perfused hearts were challenged with low-flow ischemia/reperfusion to assess the impact of meldonium on post-ischemic recovery. Meldonium had no significant effect on blood glucose concentrations or on baseline cardiac function. However, hyperpolarized magnetic resonance revealed that meldonium treatment elevated pyruvate dehydrogenase Flux by 3.1-fold and 1.2-fold in diabetic and control animals, respectively, suggesting an increase in cardiac glucose oxidation. Hyperpolarized magnetic resonance further demonstrated that meldonium reduced the normalized acetylcarnitine signal by 2.1-fold in both diabetic and control animals. The increase in pyruvate dehydrogenase Flux in vivo was accompanied by an improvement in post-ischemic function ex vivo, as meldonium elevated the rate pressure product by 1.3-fold and 1.5-fold in the control and diabetic animals, respectively. In conclusion, meldonium improves in vivo pyruvate dehydrogenase Flux in the diabetic heart, contributing to improved cardiac recovery after ischemia.
-
Hyperpolarized magnetic resonance shows that the antiischemic drug meldonium leads to Increased Flux through pyruvate dehydrogenase in vivo resulting in improved postischemic function in the diabetic heart
NMR in biomedicine, 2021Co-Authors: Dragana Savic, Vicky Ball, David Hauton, M. Kate Curtis, Lisa C. Heather, L Holster, Kerstin N. Timm, Damian J. TylerAbstract:The diabetic heart has a decreased ability to metabolize glucose. The anti-ischemic drug meldonium may provide a route to counteract this by reducing l-carnitine levels, resulting in improved cardiac glucose utilization. Therefore, the aim of this study was to use the novel technique of hyperpolarized magnetic resonance to investigate the in vivo effects of treatment with meldonium on cardiac metabolism and function in control and diabetic rats. Thirty-six male Wistar rats were injected either with vehicle, or with streptozotocin (55 mg/kg) to induce a model of type 1 diabetes. Daily treatment with either saline or meldonium (100 mg/kg/day) was undertaken for three weeks. in vivo cardiac function and metabolism were assessed with CINE MRI and hyperpolarized magnetic resonance respectively. Isolated perfused hearts were challenged with low-flow ischemia/reperfusion to assess the impact of meldonium on post-ischemic recovery. Meldonium had no significant effect on blood glucose concentrations or on baseline cardiac function. However, hyperpolarized magnetic resonance revealed that meldonium treatment elevated pyruvate dehydrogenase Flux by 3.1-fold and 1.2-fold in diabetic and control animals, respectively, suggesting an increase in cardiac glucose oxidation. Hyperpolarized magnetic resonance further demonstrated that meldonium reduced the normalized acetylcarnitine signal by 2.1-fold in both diabetic and control animals. The increase in pyruvate dehydrogenase Flux in vivo was accompanied by an improvement in post-ischemic function ex vivo, as meldonium elevated the rate pressure product by 1.3-fold and 1.5-fold in the control and diabetic animals, respectively. In conclusion, meldonium improves in vivo pyruvate dehydrogenase Flux in the diabetic heart, contributing to improved cardiac recovery after ischemia.
-
Hyperpolarized Magnetic Resonance Shows that the Anti-Ischemic Drug, Meldonium, Leads to Increased Flux Through Pyruvate Dehydrogenase In Vivo Resulting in Improved Post-Ischemic Function in the Diabetic Heart.
2020Co-Authors: Dragana Savic, Vicky Ball, Lorenz Holzner, David Hauton, Kerstin Timm, M. Kate Curtis, Lisa C. Heather, Damian J. TylerAbstract:Abstract Background: The diabetic heart has a decreased ability to metabolize glucose. The anti-ischemic drug, Meldonium, may provide a route to counteract this by reducing L-carnitine levels, resulting in improved cardiac glucose utilization. Therefore, the aim of this study was to use the novel technique of hyperpolarized magnetic resonance to investigate the in vivo effects of treatment with Meldonium on cardiac metabolism and function in control and diabetic rats. Methods: 36 male Wistar rats were injected with either placebo or streptozotocin (55mg/kg) to induce a model of type-1 diabetes. Daily treatment with either saline or Meldonium (100mg/kg/day) was undertaken for three weeks. In vivo cardiac function and metabolism were assessed with CINE MRI and hyperpolarized magnetic resonance respectively. Isolated perfused hearts were challenged with low-flow ischemia/reperfusion to assess the impact of Meldonium on post-ischemic recovery.Results: Meldonium had no significant effect on blood glucose levels or on baseline cardiac function. However, hyperpolarized magnetic resonance revealed that Meldonium treatment elevated pyruvate dehydrogenase Flux by 3.1-fold and 1.2-fold in diabetic and control animals respectively, indicating an increase in cardiac glucose oxidation. Hyperpolarized magnetic resonance further demonstrated that Meldonium reduced acetylcarnitine by 2.1-fold in both diabetic and control animals. The increase in in vivo glucose oxidation was accompanied by an improvement in ex vivo post-ischemic function, where Meldonium elevated rate pressure product by 1.3-fold and 1.5-fold in the control and diabetic animals respectively. Conclusion: Meldonium improves in vivo glucose utilization in the diabetic heart, contributing to improved cardiac recovery post-ischemia.
Qin Wang - One of the best experts on this subject based on the ideXlab platform.
-
Increased Flux through the TCA cycle enhances bacitracin production by Bacillus licheniformis DW2.
Applied microbiology and biotechnology, 2018Co-Authors: Zhaoyuan Liu, Christopher T. Nomura, Shouwen Chen, Yong Yang, Qin WangAbstract:The dodecapeptide antibiotic bacitracin, produced by several strains of Bacillus licheniformis and Bacillus subtilis, is widely used as an antibacterial animal feed additive. Several genetic strategies were explored to enhance its production. The availability of building block amino acids for bacitracin production was found to play an important role in its synthesis. In this study, the TCA cycle in the industrial strain B. licheniformis DW2 was strengthened by overexpression of the key enzymes citrate synthase and isocitrate dehydrogenase (ICDH). As the central metabolic pathway, the TCA cycle is a major source for energy supply and intermediates for anabolism. By enhancing Flux through the TCA cycle, more energy and precursors were generated for amino acid biosynthesis and uptake, resulting in enlarged intracellular pool of bacitracin-containing amino acids for bacitracin production. This study unveiled the metabolic responses of the Increased TCA cycle Flux in B. licheniformis and provided a novel strategy for enhancing bacitracin production.
Dragana Savic - One of the best experts on this subject based on the ideXlab platform.
-
hyperpolarized magnetic resonance shows that the anti ischemic drug meldonium leads to Increased Flux through pyruvate dehydrogenase in vivo resulting in improved post ischemic function in the diabetic heart
NMR in Biomedicine, 2021Co-Authors: Dragana Savic, Vicky Ball, David Hauton, M. Kate Curtis, Lisa C. Heather, L Holster, Kerstin N. Timm, Damian J. TylerAbstract:The diabetic heart has a decreased ability to metabolize glucose. The anti-ischemic drug meldonium may provide a route to counteract this by reducing l-carnitine levels, resulting in improved cardiac glucose utilization. Therefore, the aim of this study was to use the novel technique of hyperpolarized magnetic resonance to investigate the in vivo effects of treatment with meldonium on cardiac metabolism and function in control and diabetic rats. Thirty-six male Wistar rats were injected either with vehicle, or with streptozotocin (55 mg/kg) to induce a model of type 1 diabetes. Daily treatment with either saline or meldonium (100 mg/kg/day) was undertaken for three weeks. in vivo cardiac function and metabolism were assessed with CINE MRI and hyperpolarized magnetic resonance respectively. Isolated perfused hearts were challenged with low-flow ischemia/reperfusion to assess the impact of meldonium on post-ischemic recovery. Meldonium had no significant effect on blood glucose concentrations or on baseline cardiac function. However, hyperpolarized magnetic resonance revealed that meldonium treatment elevated pyruvate dehydrogenase Flux by 3.1-fold and 1.2-fold in diabetic and control animals, respectively, suggesting an increase in cardiac glucose oxidation. Hyperpolarized magnetic resonance further demonstrated that meldonium reduced the normalized acetylcarnitine signal by 2.1-fold in both diabetic and control animals. The increase in pyruvate dehydrogenase Flux in vivo was accompanied by an improvement in post-ischemic function ex vivo, as meldonium elevated the rate pressure product by 1.3-fold and 1.5-fold in the control and diabetic animals, respectively. In conclusion, meldonium improves in vivo pyruvate dehydrogenase Flux in the diabetic heart, contributing to improved cardiac recovery after ischemia.
-
Hyperpolarized magnetic resonance shows that the antiischemic drug meldonium leads to Increased Flux through pyruvate dehydrogenase in vivo resulting in improved postischemic function in the diabetic heart
NMR in biomedicine, 2021Co-Authors: Dragana Savic, Vicky Ball, David Hauton, M. Kate Curtis, Lisa C. Heather, L Holster, Kerstin N. Timm, Damian J. TylerAbstract:The diabetic heart has a decreased ability to metabolize glucose. The anti-ischemic drug meldonium may provide a route to counteract this by reducing l-carnitine levels, resulting in improved cardiac glucose utilization. Therefore, the aim of this study was to use the novel technique of hyperpolarized magnetic resonance to investigate the in vivo effects of treatment with meldonium on cardiac metabolism and function in control and diabetic rats. Thirty-six male Wistar rats were injected either with vehicle, or with streptozotocin (55 mg/kg) to induce a model of type 1 diabetes. Daily treatment with either saline or meldonium (100 mg/kg/day) was undertaken for three weeks. in vivo cardiac function and metabolism were assessed with CINE MRI and hyperpolarized magnetic resonance respectively. Isolated perfused hearts were challenged with low-flow ischemia/reperfusion to assess the impact of meldonium on post-ischemic recovery. Meldonium had no significant effect on blood glucose concentrations or on baseline cardiac function. However, hyperpolarized magnetic resonance revealed that meldonium treatment elevated pyruvate dehydrogenase Flux by 3.1-fold and 1.2-fold in diabetic and control animals, respectively, suggesting an increase in cardiac glucose oxidation. Hyperpolarized magnetic resonance further demonstrated that meldonium reduced the normalized acetylcarnitine signal by 2.1-fold in both diabetic and control animals. The increase in pyruvate dehydrogenase Flux in vivo was accompanied by an improvement in post-ischemic function ex vivo, as meldonium elevated the rate pressure product by 1.3-fold and 1.5-fold in the control and diabetic animals, respectively. In conclusion, meldonium improves in vivo pyruvate dehydrogenase Flux in the diabetic heart, contributing to improved cardiac recovery after ischemia.
-
Hyperpolarized Magnetic Resonance Shows that the Anti-Ischemic Drug, Meldonium, Leads to Increased Flux Through Pyruvate Dehydrogenase In Vivo Resulting in Improved Post-Ischemic Function in the Diabetic Heart.
2020Co-Authors: Dragana Savic, Vicky Ball, Lorenz Holzner, David Hauton, Kerstin Timm, M. Kate Curtis, Lisa C. Heather, Damian J. TylerAbstract:Abstract Background: The diabetic heart has a decreased ability to metabolize glucose. The anti-ischemic drug, Meldonium, may provide a route to counteract this by reducing L-carnitine levels, resulting in improved cardiac glucose utilization. Therefore, the aim of this study was to use the novel technique of hyperpolarized magnetic resonance to investigate the in vivo effects of treatment with Meldonium on cardiac metabolism and function in control and diabetic rats. Methods: 36 male Wistar rats were injected with either placebo or streptozotocin (55mg/kg) to induce a model of type-1 diabetes. Daily treatment with either saline or Meldonium (100mg/kg/day) was undertaken for three weeks. In vivo cardiac function and metabolism were assessed with CINE MRI and hyperpolarized magnetic resonance respectively. Isolated perfused hearts were challenged with low-flow ischemia/reperfusion to assess the impact of Meldonium on post-ischemic recovery.Results: Meldonium had no significant effect on blood glucose levels or on baseline cardiac function. However, hyperpolarized magnetic resonance revealed that Meldonium treatment elevated pyruvate dehydrogenase Flux by 3.1-fold and 1.2-fold in diabetic and control animals respectively, indicating an increase in cardiac glucose oxidation. Hyperpolarized magnetic resonance further demonstrated that Meldonium reduced acetylcarnitine by 2.1-fold in both diabetic and control animals. The increase in in vivo glucose oxidation was accompanied by an improvement in ex vivo post-ischemic function, where Meldonium elevated rate pressure product by 1.3-fold and 1.5-fold in the control and diabetic animals respectively. Conclusion: Meldonium improves in vivo glucose utilization in the diabetic heart, contributing to improved cardiac recovery post-ischemia.
U. Hübner - One of the best experts on this subject based on the ideXlab platform.
-
Increased Flux pinning in YBa2Cu3O7−δ thin-film devices through embedding of Au nano crystals
EPL (Europhysics Letters), 2011Co-Authors: C. Katzer, Mathias V. Schmidt, P. Michalowski, D. Kuhwald, Frank Schmidl, V. Grosse, S. Treiber, C. Stahl, Joachim Albrecht, U. HübnerAbstract:We prepared direct-current superconducting quantum interference device (dc-SQUID) gradiometers consisting of a single YBa2Cu3O7- δ (YBCO) layer on SrTiO3 (STO) bicrystal substrates. The superconducting thin film was modified by embedding crystalline gold nanoparticles. We investigated the growth conditions of these particles as well as their influence on the properties of the YBCO thin film. In our magneto-optical measurements we found that the presence of embedded nano crystals results in a distinct enhancement of jc over the whole investigated temperature range. We attribute the higher critical current density to an Increased pinning, which also results in a reduction of the Flux noise of our investigated gradiometers.
-
Increased Flux pinning in yba2cu3o7 δ thin film devices through embedding of au nano crystals
EPL, 2011Co-Authors: C. Katzer, Mathias V. Schmidt, P. Michalowski, D. Kuhwald, Frank Schmidl, V. Grosse, S. Treiber, C. Stahl, Joachim Albrecht, U. HübnerAbstract:We prepared direct-current superconducting quantum interference device (dc-SQUID) gradiometers consisting of a single YBa2Cu3O7- δ (YBCO) layer on SrTiO3 (STO) bicrystal substrates. The superconducting thin film was modified by embedding crystalline gold nanoparticles. We investigated the growth conditions of these particles as well as their influence on the properties of the YBCO thin film. In our magneto-optical measurements we found that the presence of embedded nano crystals results in a distinct enhancement of jc over the whole investigated temperature range. We attribute the higher critical current density to an Increased pinning, which also results in a reduction of the Flux noise of our investigated gradiometers.
T Matsuura - One of the best experts on this subject based on the ideXlab platform.
-
synthesis and characterization of novel water soluble derivative of chitosan as an additive for polysulfone ultrafiltration membrane
Journal of Membrane Science, 2013Co-Authors: Rajesha Kumar, Arun M Isloor, Ahmad Fauzi Ismail, T MatsuuraAbstract:A novel water soluble Chitosan derivative N-propylphosphonic Chitosan (NPPCS) having a terminal phosphonic acid group was synthesized by reacting Chitosan with Hydroxybenzotriazole (HOBt) and propylphosphonic anhydride (T3P)® via one pot reaction. The novel derivative was characterized by 1H NMR, Attenuated Total Reflectance Infra Red (ATR-IR) spectroscopy and XRD. Due to insolubility of NPPCS in organic solvents, a new process was demonstrated for blending of NPPCS with Polysulfone. The proper blending of NPPCS with Polysulfone was confirmed by ATR-IR spectroscopy. The improved hydrophilicity of PSf/NPPCS membranes was confirmed by contact angle measurement. The permeation studies showed Increased Flux of PSf/NPPCS membranes as compared to the pristine Polysulfone membrane. The antifouling property of PSf/NPPCS membrane was determined by Bovine Serum Albumin (BSA) protein rejection studies. The membranes showed the enhanced antifouling property as compared to pristine Polysulfone membranes with a maximum of 74% Flux recovery ratio (FRR) value.
